CPL
DMAC icon

Capital & Planning LLC’s DiaMedica Therapeutics DMAC Stock Holding History

Capital & Planning LLC’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5K Buy
+2,001
New +$15.9K 0.01% 90

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital & Planning LLC's DMAC Position: Q1 2026 in Review

Capital & Planning LLC opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 2,001 shares worth $13.5K. The stake represents 0.01% of the portfolio and ranks #90 among its holdings.

98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Capital & Planning LLC held 2,001 shares of DiaMedica Therapeutics worth $13.5K as of Q1 2026.
  • DiaMedica Therapeutics was a new Capital & Planning LLC position in Q1 2026.
  • DiaMedica Therapeutics made up 0.01% of Capital & Planning LLC's portfolio in Q1 2026, its #90 holding.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Capital & Planning LLC's 13F filing for Q1 2026, filed 18 May 2026.